SHOCKING: 2 | Mind Blowing Facts

UCB's Rare Childhood Epilepsy Drug Scores FDA Approval

The FDA approved UCB SA's (OTC:UCBJY) drug to treat seizures associated with Lennox-Gastaut Syndrome (LGS), a rare form of childhood epilepsy. The drug, branded as Fintepla, is approved in the U.S. to treat another form of childhood-onset epilepsy, Davet Syndrome (DS), in patients aged two years and older. LGS causes cognitive dysfunction and…

Benzinga · Mar 28, 2022

UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study

UCB SA (OTC: UCBJF) 

Benzinga · Jan 21, 2022

52 Biggest Movers From Yesterday

Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares surged 65.7% to close at $25.92 on Wednesday after the company announced it will be acquired by UCB for approximately $1.9 billion.

Benzinga · Jan 20, 2022